Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wataru Hamaguchi is active.

Publication


Featured researches published by Wataru Hamaguchi.


Bioorganic & Medicinal Chemistry | 2013

Design and synthesis of novel benzimidazole derivatives as phosphodiesterase 10A inhibitors with reduced CYP1A2 inhibition.

Wataru Hamaguchi; Naoyuki Masuda; Mai Isomura; Satoshi Miyamoto; Shigetoshi Kikuchi; Yasushi Amano; Kazuya Honbou; Takuma Mihara; Toshihiro Watanabe

A novel class of phosphodiesterase 10A (PDE10A) inhibitors with reduced CYP1A2 inhibition were designed and synthesized starting from 2-{[(1-phenyl-1H-benzimidazol-6-yl)oxy]methyl}quinoline (1). Introduction of an isopropyl group at the 2-position and a methoxy group at the 5-position of the benzimidazole ring of lead compound 1 resulted in the identification of 2-{[(2-isopropyl-5-methoxy-1-phenyl-1H-benzimidazol-6-yl)oxy]methyl}quinoline (25b), which exhibited potent PDE10A inhibitory activity with reduced CYP1A2 inhibitory activity compared to compound 1.


Bioorganic & Medicinal Chemistry | 2012

Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists

Kenji Negoro; Yasuhiro Yonetoku; Hana Misawa-Mukai; Wataru Hamaguchi; Tatsuya Maruyama; Shigeru Yoshida; Makoto Takeuchi; Mitsuaki Ohta

Novel 4-amino-2-phenylpyrimidine derivatives were synthesized and evaluated as GPR119 agonists. Optimization of the substituents on the phenyl ring at the 2-position and the amino group at the 4-position led to the identification of 3,4-dihalogenated and 2,4,5-trihalogenated phenyl derivatives showing potent GPR119 agonistic activity. The advanced analog (2R)-3-{[2-(4-chloro-2,5-difluorophenyl)-6-ethylpyrimidin-4-yl]amino}propane-1,2-diol (24g) was found to improve glucose tolerance at 1mg/kg po in mice and to show excellent pharmacokinetic profiles in mice and monkeys. Compound 24g also showed an excellent antidiabetic effect in diabetic kk/Ay mice after one week of single daily treatment. These results demonstrate that novel GPR119 agonist 24g improves glucose tolerance not only by enhancing glucose-dependent insulin secretion but also by preserving pancreatic β-cell function.


Bioorganic & Medicinal Chemistry | 2015

Synthesis, SAR study, and biological evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors with reduced CYP3A4 inhibition

Wataru Hamaguchi; Naoyuki Masuda; Satoshi Miyamoto; Yasuhiro Shiina; Shigetoshi Kikuchi; Takuma Mihara; Hiroyuki Moriguchi; Hiroshi Fushiki; Yoshihiro Murakami; Yasushi Amano; Kazuya Honbou; Kouji Hattori

A novel class of phosphodiesterase 10A inhibitors with potent PDE10A inhibitory activity and reduced CYP3A4 inhibition was designed and synthesized starting from 2-[4-({[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]oxy}methyl)phenyl]quinoline (1). Replacement of pyridine ring of 1 with N-methyl pyridone ring drastically improved CYP3A4 inhibition, and further optimization of these quinoline analogues identified 1-methyl-5-(1-methyl-3-{[4-(quinolin-2-yl)phenoxy]methyl}-1H-pyrazol-4-yl)pyridin-2(1H)-one (42b), which showed potent PDE10A inhibitory activity and a good CYP3A4 inhibition profile. A PET study with (11)C-labeled 42b indicated that 42b exhibited good brain penetration and specifically accumulated in the rodent striatum. Further, oral administration of 42b dose-dependently attenuated phencyclidine-induced hyperlocomotion in mice with an ED50 value of 2.0mg/kg and improved visual-recognition memory impairment at 0.1 and 0.3mg/kg in mice novel object recognition test.


Bioorganic & Medicinal Chemistry | 2012

Synthesis and biological evaluation of (4H-1,2,4-triazol-4-yl)isoquinoline derivatives as selective glycine transporter 1 inhibitors.

Takashi Sugane; Takahiko Tobe; Wataru Hamaguchi; Itsuro Shimada; Kyoichi Maeno; Junji Miyata; Takeshi Suzuki; Tetsuya Kimizuka; Takuma Morita; Shuichi Sakamoto; Shin-ichi Tsukamoto

To identify novel glycine transporter 1(GlyT1) inhibitors with greater selectivity relative to GlyT2 and improved aqueous solubility, we synthesized a series of 4H-1,2,4-triazole derivatives with heteroaromatic rings at the 4-position and investigated their structure-activity relationships. Replacement of the 2-fluorophenyl group of lead compound 5 with various aromatic groups led to the identification of 5-(3-biphenyl-4-yl-5-ethyl-4H-1,2,4-triazol-4-yl)isoquinoline (15) with 38-fold selectivity between GlyT1 and GlyT2. 15 also showed improved aqueous solubility and in vivo efficacy on (+)-HA966-induced hyperlocomotion in mice over the lead compound.


Bioorganic & Medicinal Chemistry | 2015

Addressing phototoxicity observed in a novel series of biaryl derivatives: discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436.

Wataru Hamaguchi; Naoyuki Masuda; Satoshi Miyamoto; Shigetoshi Kikuchi; Fumie Narazaki; Yasuhiro Shiina; Ryushi Seo; Yasushi Amano; Takuma Mihara; Hiroyuki Moriguchi; Kouji Hattori

We synthesized several biaryl derivatives as PDE10A inhibitors to prevent phototoxicity of 2-[4-({[1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl]oxy}methyl)phenyl]quinoline (1) and found that the energy difference between the energy-minimized conformation and the coplanar conformation of the biaryl moiety helped facilitate prediction of the phototoxic potential of biaryl compounds. Replacement of the quinoline ring of 1 with N-methyl benzimidazole increased this energy difference and prevented phototoxicity in the 3T3 NRU test. Further optimization identified 1-methyl-5-(1-methyl-3-{[4-(1-methyl-1H-benzimidazol-4-yl)phenoxy]methyl}-1H-pyrazol-4-yl)pyridin-2(1H)-one (38b). Compound 38b exhibited good selectivity against other PDEs, and oral administration of 38b improved visual-recognition memory deficit in mice at doses of 0.001 and 0.003mg/kg in the novel object recognition test. ASP9436 (sesquiphosphate of 38b) may therefore be used for the treatment of schizophrenia with a low risk of phototoxicity.


Bioorganic & Medicinal Chemistry | 2009

Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines.

Kazuhiro Yokoyama; Noriko Ishikawa; Susumu Igarashi; Noriyuki Kawano; Naoyuki Masuda; Wataru Hamaguchi; Shingo Yamasaki; Yohei Koganemaru; Kazuyuki Hattori; Takahiro Miyazaki; Shin-ichi Ogino; Yuzo Matsumoto; Makoto Takeuchi; Mitsuaki Ohta


Archive | 2004

INDOLE OR INDAZOLE DERIVATIVE

Wataru Hamaguchi; Koji Kato; Yohei Koganemaru; Noriyuki Kono; Naoyuki Masuda; Takahiro Miyazaki; 浩二 加藤; 直之 増田; 宇広 宮▲ざき▼; 陽平 小金丸; 則征 河野


Chemical & Pharmaceutical Bulletin | 2014

Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors.

Wataru Hamaguchi; Naoyuki Masuda; Kiyohiro Samizu; Takuma Mihara; Kaori Takama; Toshihiro Watanabe


Tetrahedron-asymmetry | 2012

Practical and efficient synthesis of the (R)-atropisomer of a 4-phenyl 1,2,4-triazole derivative as a selective GlyT1 inhibitor

Takashi Sugane; Noritaka Hamada; Takahiko Tobe; Wataru Hamaguchi; Itsuro Shimada; Kyoichi Maeno; Junji Miyata; Takeshi Suzuki; Tetsuya Kimizuka; Shuichi Sakamoto; Shin-ichi Tsukamoto


Archive | 2010

Nitrogenous-ring acylguanidine derivative

Isao Kinoyama; Takehiro Miyazaki; Yohei Koganemaru; Takuya Washio; Wataru Hamaguchi

Collaboration


Dive into the Wataru Hamaguchi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge